COVID-19 treated with oral Nirmatrelvir-Ritonavir in 3 children.
10.3760/cma.j.cn112140-20220701-00608
- Author:
Shuang SHI
1
;
Na DONG
1
;
Ying DING
1
;
Chao WANG
1
;
Lang YUAN
1
;
Yong Shuang FANG
1
;
Bing Jie WANG
1
;
Yan Hua NIU
1
;
Zhen Zhen WEI
1
;
Tian PU
1
;
Xiao Yan DONG
1
;
Quan LU
1
Author Information
1. Department of Respiratory Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200062, China.
- Publication Type:Journal Article
- MeSH:
Child;
Male;
Humans;
Female;
COVID-19;
SARS-CoV-2;
Ritonavir/therapeutic use*;
Retrospective Studies;
China;
Nucleic Acids;
COVID-19 Drug Treatment
- From:
Chinese Journal of Pediatrics
2022;60(11):1168-1171
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To summarize the application experience and the therapeutic effect of Nirmatrelvir-Ritonavir (trade name: Paxlovid) for COVID-19 in children. Methods: A retrospective analysis was performed on the clinical data, including collecting the clinical manifestations and clinical outcomes, dynamically monitoring the blood routine, hepatic and renal function and SARS-CoV-2 nucleic acid results, and observing the related side effects during the treatment, etc, of 3 cases with COVID-19 treated with Paxlovid admitted to Shanghai Children's Hospital (designated referral hospital for SARS-CoV-2 infection in Shanghai) from May 1st to June 1st, 2022. Results: The 3 cases were 12, 14, 17 years of age, among which 2 cases were males, 1 case was female. All 3 cases were mild cases with underlying diseases and risk of developing into severe COVID-19, with symptoms of high fever, sore throat and dry cough. The treatment of Paxlovid at 3rd day of symptom onset contributed to the symptom-free after 1-2 days and negative results of SARS-CoV-2 nucleic acid after 2-4 days. All patients had no adverse manifestations of gastrointestinal tract and nervous system but a case had little skin rashes, which recovered after the withdrawal of Paxlovid. Three cases had normal hepatic and renal function during the Paxlovid treatment. At 3 months after discharge, no clinical manifestations of post-COVID syndrome were found in all 3 cases. Conclusion: Paxlovid was effective and relatively safe in the treatment of 3 children with COVID-19.
